GeneHealth - Your precision medicine

Erythromelalgia

Disease Details

Family Health Simplified

Buy Membership

Description: Erythromelalgia is a rare condition characterized by episodes of burning pain, redness, and increased temperature mainly affecting the extremities.
Type: Erythromelalgia is a rare condition that primarily affects the skin and extremities, characterized by episodes of severe burning pain, warmth, and redness. The primary type of genetic transmission for erythromelalgia is autosomal dominant.
Signs And Symptoms: Signs and symptoms of erythromelalgia include:

1. **Burning Pain**: Intense, episodic burning pain in the extremities, often feet and sometimes hands.
2. **Redness**: A noticeable redness or erythema in the affected areas.
3. **Warmth**: Increased temperature in the affected regions.
4. **Swelling**: Possible swelling or edema in the painful areas.
5. **Triggers**: Pain episodes often triggered by heat, exercise, or wearing tight-fitting shoes.
6. **Duration**: Symptoms can last from a few minutes to several hours and often improve with cooling or elevating the affected limbs.
Prognosis: The prognosis for erythromelalgia varies. Some individuals may experience intermittent symptoms that can be managed with lifestyle changes and medication, leading to a relatively normal quality of life. Others may suffer from more severe, persistent symptoms that are refractory to treatment, significantly impacting daily activities and quality of life. Early diagnosis and individualized treatment plans are essential for improving outcomes.
Onset: Erythromelalgia usually manifests with a variable onset, which can occur at any age but often starts in middle age. The exact cause can be primary (genetic) or secondary to other conditions such as autoimmune diseases, myeloproliferative disorders, or certain medications. The hallmark symptoms are burning pain, redness, and increased skin temperature, typically affecting the extremities.
Prevalence: The prevalence of erythromelalgia is not well-documented and can vary. It is considered a rare condition, with some estimates suggesting it affects 1 to 2 individuals per 100,000 people.
Epidemiology: Only a small number of studies that have investigated the prevalence of EM, with four studies conducted to date.
The mean of all the studies combined results in an EM estimation incidence of 4.7/100,000 with a mean of 1 : 3.7 of the male to female ratio, respectively.In 1997 there was a study conducted in Norway that estimated that the annual incidence of 2/100,000, with a 1 : 2.4 male to female ratio in this study
population, respectively. In 2009 there was a population-based study of EM in the USA (Olmsted County, Minnesota), that reported that the annual incidence was 1.3/100,000, with a 1 : 5.6 male to female ratio in this study population, respectively.
The incidence in this study of primary and secondary EM was 1.1 : 0.2 per 100 000 people per year, respectively.
A study of a single centre in the south of Sweden in 2012, showed the overall annual population-based incidence was 0.36/100,000.
In New Zealand (Dunedin) a study estimated that in 2013 the incidence of EM is 15/100,000, with a 1 : 3 male to female ratio in this study
population, respectively. This last study has an estimation that is at least ten times higher than the prevalence previously reported. This study recruited individuals based on self-identification of symptoms (after self-identification, patients were invited for an assessment of an EM diagnosis), instead of participants that are identified through secondary and tertiary referrals as in the other studies.
Intractability: Erythromelalgia can be intractable for some individuals, meaning that it can be resistant to standard treatments and difficult to manage. The severity and responsiveness to treatment can vary widely among patients. Collaborating with healthcare providers to find the most effective management strategies is crucial.
Disease Severity: Erythromelalgia is a rare disorder characterized by episodes of burning pain, redness, and warmth in the extremities, particularly the hands and feet. The severity of the disease can vary widely among individuals. Some people may experience mild symptoms that are manageable with lifestyle changes and medications, while others may suffer from severe, debilitating pain that significantly impacts their quality of life. The frequency and intensity of flare-ups can also differ, with some patients having periodic episodes and others experiencing continuous discomfort.
Healthcare Professionals: Disease Ontology ID - DOID:9240
Pathophysiology: There are 10 known mutations in the voltage-gated sodium channel α-subunit NaV1.7 encoding gene, SCN9A. This channel is expressed primarily in nociceptors of the dorsal root ganglion and the sympathetic ganglion neurons. Nine of these mutations have received further study and they have all shown to result in similar biophysical alterations, Table 1. As can be seen from table 1, the primary effect of erythromelalgia mutations is NaV1.7 channels that activate at more hyperpolarized potentials. NaV1.7 channels act largely as threshold sensors and initiate action potentials. Consequently, this shift in their activation profile results in channels that open closer to the resting membrane potential. In many mutations, this shift of activation is accompanied by shifts in the voltage sensitivity of fast and/or slow inactivation, often in the depolarized direction. This results in channels that are open for a longer of period of time, producing larger and more prolonged changes in membrane potential.Some of these mutant channels have been expressed in dorsal root ganglion (DRG) or sympathetic neurons. In DRG neurons expressing the F1449V mutation, a lower threshold is required for action potential creation (93.1 ± 12.0 pA) than those expressing wild-type channels (124.1 ± 7.4 pA). Furthermore, while DRG neurons expressing wild-type channels only respond with a few action potentials, those expressing F1449V channels respond with a high-frequency train of action potentials. There is a similar effect in DRG neurons expressing the L858H and A863P mutants. Here, there is also a notable change in resting membrane potential, being depolarized by 4-7 mV versus wild-type channel expressing cells. The situation is different, however, in sympathetic neurons expressing the L858H mutation. While L858H expressing sympathetic ganglion are depolarized ~5mV relative to wild-type expressing neurons, their threshold for action potential initiation is notably higher. Furthermore, while current injection of 40pA for 950ms provokes an average of 6 action potentials in sympathetic neurons expressing wild-type channels this stimulation evokes only approximately 2 action potentials with reduced overshoots in sympathetic neurons expressing L858H mutant channels. Further investigation has demonstrated that the differences in response between DRG and sympathetic neurons is due to expression of NaV1.8 in the former. Consequently, expression of NaV1.8 channels in sympathetic neurons also expressing L858H mutant NaV1.7 results in neurons with a depolarized resting membrane potential that nevertheless have a normal action potential threshold and overshoot.An effective, though not recommended, treatment for erythromelalgia symptoms is cooling of the affected area. Activation of wild-type channels is unaffected by cooling. L858F mutant channels, however, are activated at more depolarized potentials when cooled than at normal body temperature. At 16 °C the activation V½ of the mutant channel is only 4.6mV more hyperpolarized that wild-type versus 9.6mV more hyperpolarized at 35 °C. Fast inactivation is affected in a similar manner in both wild-type and L858F mutant channel and is, thus, unlikely to contribute to symptom resolution due to cooling. While such cooling is unlikely to affect neuronal cell bodies, axons and termini express NaV1.7 and are present in the skin.
Carrier Status: Erythromelalgia does not typically involve a carrier status as it is not a recessive genetic disorder. It is often caused by mutations in the SCN9A gene or can occur secondary to other conditions.
Mechanism: Erythromelalgia is a rare condition characterized by episodes of burning pain, warmth, and redness in the extremities. The mechanism behind these symptoms involves abnormalities in blood vessel function and nerve signaling.

Molecular mechanisms underlying erythromelalgia often include mutations in the SCN9A gene, which encodes the voltage-gated sodium channel Nav1.7. Mutations in this gene lead to hyperexcitability of sensory neurons, resulting in abnormal pain signaling. This hyperexcitability causes the blood vessels in affected areas to dilate excessively, contributing to the characteristic redness and warmth.
Treatment: For secondary erythromelalgia, treatment of the underlying primary disorder is the most primary method of treatment. Although aspirin has been thought to reduce symptoms of erythromelalgia, it is rare to find evidence that this is effective. Mechanical cooling of the limbs by elevating them can help or managing the ambient environment frequently is often necessary constantly as flares occur due to sympathetic autonomic dysfunction of the capillaries. The pain that accompanies it is severe and treated separately (the pain is similar to CRPS, phantom limb or thalamic pain syndrome). Patients are strongly advised not to place the affected limbs in cold water to relieve symptoms when flaring occurs. It may seem a good idea, but it precipitates problems further down the line causing damage to the skin and ulceration often intractable due to the damaged skin. A possible reduction in skin damage may be accomplished by enclosing the flaring limb in a commonly available, thin, heat transparent, water impermeable, plastic food storage bag. The advice of a physician is advised depending on specific circumstances.Primary erythromelalgia management is symptomatic, i.e. treating painful symptoms only. Specific management tactics include avoidance of attack triggers such as: heat, change in temperature, exercise or over exertion, alcohol and spicy foods. This list is by no means comprehensive as there are many triggers to set off a 'flaring' episode that are inexplicable. Whilst a cool environment is helpful in keeping the symptoms in control, the use of cold water baths is strongly discouraged. In pursuit of added relief sufferers can inadvertently cause tissue damage or death, i.e. necrosis. See comments at the end of the preceding paragraph regarding possible effectiveness of plastic food storage bags to avoid/reduce negative effects of submersion in cold water baths.One clinical study has demonstrated the efficacy of IV lidocaine or oral mexilitine, though differences between the primary and secondary forms were not studied. Another trial has shown promise for misoprostol, while other have shown that gabapentin, venlafaxine and oral magnesium may also be effective, but no further testing was carried out as newer research superseded this combination.Strong anecdotal evidence from EM patients shows that a combination of drugs such as duloxetine and pregabalin is an effective way of reducing the stabbing pains and burning sensation symptoms of erythromelalgia in conjunction with the appropriate analgesia. In some cases, antihistamines may give some relief. Most people with erythromelalgia never go into remission and the symptoms are ever present at some level, whilst others get worse, or the EM is eventually a symptom of another disease such as systemic scleroderma.Some suffering with EM are prescribed ketamine topical creams as a way of managing pain on a long-term basis. Feedback from some EM patients has led to reduction in usage as they believe it is only effective for short periods.Living with erythromelalgia can result in a deterioration in quality of life resulting in the inability to function in a work place, lack of mobility, depression, and is socially alienating; much greater education of medical practitioners is needed. As with many rare diseases, many people with EM end up taking years to get a diagnosis and to receive appropriate treatment.Research into the genetic mutations continues but there is a paucity of clinical studies focusing on living with erythromelalgia. There is much urgency within pharmaceutical companies to provide a solution to those who suffer with pain such as that with erythromelalgia.
Compassionate Use Treatment: Erythromelalgia is a rare condition that can be challenging to treat. Here are some compassionate use, off-label, or experimental treatments that have been explored:

1. **Capsaicin Cream**: Applied topically, it can help desensitize nerves and reduce pain.

2. **Intravenous Lidocaine**: This has been used in some severe cases to provide pain relief.

3. **Sodium Channel Blockers**: Medications like mexiletine, which block sodium channels, are sometimes used off-label to manage symptoms.

4. **Anticonvulsants**: Drugs such as gabapentin and pregabalin have been used off-label to manage neuropathic pain associated with erythromelalgia.

5. **Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)**: Duloxetine is sometimes prescribed off-label for its pain-relieving properties.

6. **ACVR1/ALK2 Inhibitors**: These are considered experimental treatments and are currently under investigation.

Consultation with a healthcare provider is crucial for determining the most appropriate treatment in individual cases.
Lifestyle Recommendations: For erythromelalgia, the following lifestyle recommendations may help manage the symptoms:

1. **Avoid Triggers**: Identify and avoid known triggers such as heat, prolonged standing, and certain foods or medications that worsen symptoms.

2. **Cool Environment**: Stay in a cool environment and use air conditioning or fans to help manage symptoms.

3. **Cooling Measures**: Apply cool (not ice-cold) compresses or immerse affected areas in cool water; avoid extreme cold to prevent tissue damage.

4. **Elevation**: Elevate the affected limbs to help reduce swelling and discomfort.

5. **Loose Clothing**: Wear loose, lightweight, and breathable clothing to avoid constriction and overheating.

6. **Stay Hydrated**: Drink plenty of water to stay hydrated and maintain proper circulation.

7. **Regular Exercise**: Engage in moderate, appropriate physical activity to improve circulation, but avoid activities that cause overheating.

8. **Stress Management**: Practice stress-relief techniques such as mindfulness, meditation, or yoga as stress can exacerbate symptoms.

9. **Avoid Alcohol and Spicy Foods**: Some patients report that alcohol and spicy foods worsen their symptoms, so limit or avoid these if necessary.

10. **Foot and Skin Care**: Take good care of your skin and feet to prevent secondary infections or complications.

Always consult a healthcare provider for personalized advice and treatment options tailored to your condition.
Medication: Erythromelalgia, a rare vascular peripheral pain disorder, is often treated with a combination of medications to manage symptoms. Common medications include:

1. **Aspirin**: Especially for secondary erythromelalgia associated with myeloproliferative disorders.
2. **Anticonvulsants**: Gabapentin and pregabalin may help alleviate pain by stabilizing neural activity.
3. **Calcium Channel Blockers**: Medications like diltiazem can aid in improving blood flow.
4. **Topical Agents**: Lidocaine or capsaicin creams may provide localized relief.
5. **Tricyclic Antidepressants**: Amitriptyline or nortriptyline can be prescribed for neuropathic pain relief.
6. **Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)**: Duloxetine and venlafaxine are used for nerve pain management.

Patients should consult a healthcare provider to determine the most appropriate treatment plan tailored to their specific condition.
Repurposable Drugs: Erythromelalgia is a rare condition characterized by episodes of burning pain, warmth, and redness in the extremities. Some repurposable drugs for managing symptoms include:

1. **Aspirin:** Often effective, especially in cases linked to myeloproliferative disorders.
2. **Gabapentin/Pregabalin:** Used for their neuropathic pain-relieving properties.
3. **Duloxetine:** An antidepressant that can help with chronic pain management.
4. **Carbamazepine:** An anticonvulsant that can alleviate pain in certain patients.
5. **Topical Lidocaine:** Provides localized pain relief.

Consult with a healthcare provider for tailored treatment.
Metabolites: For erythromelalgia, there are no specific metabolites known to be directly associated with the disease. Erythromelalgia is a rare vascular peripheral pain disorder characterized by episodes of burning pain, redness, and increased skin temperature, primarily in the extremities. The pathophysiology may involve abnormalities in sodium channels or secondary causes related to other conditions, but precise metabolites linked to it have not been well-documented.
Nutraceuticals: There is limited scientific evidence supporting the effective use of nutraceuticals for treating erythromelalgia. However, some patients have reported relief with supplements that have anti-inflammatory and vasodilatory properties. These may include:

1. Omega-3 fatty acids - known for their anti-inflammatory benefits.
2. Magnesium - can help with vascular health.
3. Alpha-lipoic acid - acts as an antioxidant.
4. Capsaicin - can provide pain relief when used topically.

It is important to consult with a healthcare professional before starting any new supplement regimen, as individual health conditions and responses to treatment can vary.
Peptides: In erythromelalgia, there is no direct, established connection to specific peptides or nanotechnology-based treatments currently approved by major health organizations. Erythromelalgia is a condition characterized by episodes of burning pain, redness, and warmth, often in the extremities. The focus of treatment is generally symptomatic relief, including cooling measures, pain management, and sometimes medications like aspirin or other vasodilators. Research into innovative treatments, including potential peptide-based therapies or nanoscale interventions, is still evolving.